InnoCare Pharma Management

Management criteria checks 3/4

InnoCare Pharma's CEO is Jasmine Cui, appointed in Aug 2016, has a tenure of 8.08 years. total yearly compensation is CN¥22.63M, comprised of 20.8% salary and 79.2% bonuses, including company stock and options. directly owns 5.73% of the company’s shares, worth HK$718.04M. The average tenure of the management team and the board of directors is 3 years and 4.5 years respectively.

Key information

Jasmine Cui

Chief executive officer

CN¥22.6m

Total compensation

CEO salary percentage	20.8%
CEO tenure	8.1yrs
CEO ownership	5.7%
Management average tenure	3yrs
Board average tenure	4.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jasmine Cui's remuneration changed compared to InnoCare Pharma's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	-CN¥471m
Mar 31 2024	n/a	n/a	-CN¥761m
Dec 31 2023	CN¥23m	CN¥5m	-CN¥631m
Sep 30 2023	n/a	n/a	-CN¥584m
Jun 30 2023	n/a	n/a	-CN¥867m
Mar 31 2023	n/a	n/a	-CN¥781m
Dec 31 2022	CN¥24m	CN¥4m	-CN¥887m
Sep 30 2022	n/a	n/a	-CN¥987m
Jun 30 2022	n/a	n/a	-CN¥296m
Mar 31 2022	n/a	n/a	-CN¥78m
Dec 31 2021	CN¥29m	CN¥3m	-CN¥65m
Sep 30 2021	n/a	n/a	CN¥60m
Jun 30 2021	n/a	n/a	-CN¥266m
Mar 31 2021	n/a	n/a	-CN¥329m
Dec 31 2020	CN¥120m	CN¥1m	-CN¥391m
Sep 30 2020	n/a	n/a	-CN¥2b
Jun 30 2020	n/a	n/a	-CN¥2b
Mar 31 2020	n/a	n/a	-CN¥2b
Dec 31 2019	CN¥17m	CN¥3m	-CN¥2b
Sep 30 2019	n/a	n/a	-CN¥742m
Jun 30 2019	n/a	n/a	-CN¥592m
Mar 31 2019	n/a	n/a	-CN¥571m
Dec 31 2018	CN¥26m	CN¥2m	-CN¥550m

Compensation vs Market: Jasmine's total compensation ($USD3.23M) is above average for companies of similar size in the Hong Kong market ($USD518.33K).

Compensation vs Earnings: Jasmine's compensation has been consistent with company performance over the past year.

CEO

Jasmine Cui (61 yo)

8.1yrs

Tenure

CN¥22,626,000

Compensation

Dr. Jisong Cui, Ph.D. also known as Jasmine, has been Co-Founder InnoCare Pharma, Ltd. and serves as Chief Executive Officer of InnoCare Pharma, Ltd. since August 18, 2016 and its Chairwoman since Septembe...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jisong Cui	Co-Founder	8.1yrs	CN¥22.63m	5.73% CN¥ 718.0m
Renbin Zhao	VP of Clinical Development & Medical Research and Executive Director	no data	CN¥4.06m	8.21% CN¥ 1.0b
Xin Fu	Chief Financial Officer	less than a year	no data	no data
Nan Gao	Chief Operating Officer	3.2yrs	no data	no data
Yue Tan	Accounting Supervisor	no data	no data	no data
Xiangyang Chen	Chief Technology Officer	4.9yrs	no data	0.0071% CN¥ 888.8k
Junsu Wang	General Counsel	3yrs	no data	no data
Davy Ouyang	VP & Head of Biology	3yrs	no data	no data
Jeff Chen	Chief Commercial Officer	less than a year	no data	no data
Bei Yuan	Secretary of the Board	no data	no data	no data
James Deng	Member of Scientific Advisory Board in Sales & Marketing	no data	no data	no data

3.0yrs

Average Tenure

52.5yo

Average Age

Experienced Management: 9969's management team is considered experienced (3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Jisong Cui	Co-Founder	8.8yrs	CN¥22.63m	5.73% CN¥ 718.0m
Renbin Zhao	VP of Clinical Development & Medical Research and Executive Director	8.8yrs	CN¥4.06m	8.21% CN¥ 1.0b
James Deng	Member of Scientific Advisory Board in Sales & Marketing	no data	no data	no data
Arnold Levine	Member of Scientific Advisory Board	no data	no data	no data
Yigong Shi	Non-Executive Director & President of Scientific Advisory Board	8.8yrs	no data	0.18% CN¥ 22.0m
Zemin Zhang	Member of Scientific Advisory Board	8.8yrs	no data	no data
Zhanguo Li	Member of Scientific Advisory Board	no data	no data	no data
Ronggang Xie	Non-Executive Director	3.5yrs	no data	no data
Kai-Xian Chen	Independent Non-Executive Director	4.5yrs	no data	no data
Lan Hu	Independent Non-Executive Director	4.5yrs	no data	no data
Ming Jin	Non-Executive Director	2.5yrs	no data	no data
Dandan Dong	Independent Non-Executive Director	less than a year	no data	no data

4.5yrs

Average Tenure

55.5yo

Average Age

Experienced Board: 9969's board of directors are considered experienced (4.5 years average tenure).

InnoCare Pharma Management

Management criteria checks 3/4

Key information

Recent management updates

InnoCare Pharma Limited Announces Board and Committee Changes

InnoCare Pharma Appoints Xin Fu as Chief Financial Officer

Innocare Pharma Limited Announces the Appointment of Dandan Dong as Independent Non-Executive Director

Innocare Pharma Limited Announces Board Changes

Less than half of directors are independent

Less than half of directors are independent

Recent updates

InnoCare Pharma Limited Announces Board and Committee Changes

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

InnoCare Pharma Limited Announces End of Phase 2 Meeting with the U.S. Food and Drug Administration Regarding the Clinical Development of Orelabrutinib for the Treatment of Multiple Sclerosis

Second quarter 2024 earnings released: CN¥0.08 loss per share (vs CN¥0.19 loss in 2Q 2023)

InnoCare Pharma Announces First Subject Dosed in Clinical Trial of TYK2 Inhibitor ICP-332 in the U.S

InnoCare Pharma Limited to Report First Half, 2024 Results on Aug 21, 2024

InnoCare Pharma Announces the Acceptance of Biologics License Application for Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Adult Patients in China

InnoCare Pharma Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

First quarter 2024 earnings released: CN¥0.08 loss per share (vs CN¥0.007 loss in 1Q 2023)

InnoCare Pharma Limited to Report Q1, 2024 Results on May 14, 2024

Full year 2023 earnings released: CN¥0.37 loss per share (vs CN¥0.60 loss in FY 2022)

InnoCare Pharma Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib

InnoCare Pharma Limited Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in China

InnoCare Pharma Limited Provides Earnings Guidance for the Year Ended 31 December 2023

InnoCare Announces First Pediatric Patient Dosed in Clinical Trial of pan-TRK Inhibitor Zurletrectinib in China

InnoCare Pharma Announces Clearance of Clinical Trial of BCL2 Inhibitor ICP-248 by U.S. FDA

New minor risk - Profitability

InnoCare Pharma Appoints Xin Fu as Chief Financial Officer

InnoCare Pharma Announces Latest Data of Oncology Pipelines Presented at the 65th Annual Meeting of ASH

Third quarter 2023 earnings released: CN¥0.062 loss per share (vs CN¥0.28 loss in 3Q 2022)

New minor risk - Profitability

InnoCare Pharma Announces First Patient Dosed in the Phase III Registrational Trial of Orelabrutinib for the Treatment of ITP in China

Innocare Pharma Limited Announces the Appointment of Dandan Dong as Independent Non-Executive Director

InnoCare Pharma Limited (SEHK:9969) commences an Equity Buyback Plan for 149,967,323 shares, representing 8.5% of its issued share capital, under the authorization approved on June 2, 2023.

InnoCare Pharma Limited (SEHK:9969) commences an Equity Buyback Plan for 149,967,323 shares, representing 8.5% of its issued share capital, under the authorization approved on June 2, 2023.

InnoCare Pharma Announces Approval of Clinical Trial of SHP2 Inhibitor ICP-189 in Combination with EGFR Inhibitor Furmonertinib

InnoCare Announces Study Result of Orelabrutinib in Patients with r/r MZL Published by American Journal of Hematology

Second quarter 2023 earnings released: CN¥0.19 loss per share (vs CN¥0.24 loss in 2Q 2022)

Innocare Pharma Limited Announces Board Changes

InnoCare Pharma Limited to Report First Half, 2023 Results on Aug 30, 2023

First quarter 2023 earnings released: CN¥0.01 loss per share (vs CN¥0.16 loss in 1Q 2022)

No longer forecast to breakeven

Full year 2022 earnings released: CN¥0.60 loss per share (vs CN¥0.047 loss in FY 2021)

Forecast breakeven date pushed back to 2025

InnoCare Pharma Limited Provides Earnings Guidance for the Year Ended 31 December 2022

InnoCare Pharma Limited Announces the Latest Clinical Result of FGFR Inhibitor Gunagratinib (ICP-192) for the Treatment of Cholangiocarcinoma Was Presented At 2023 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium

Now 27% undervalued

InnoCare Pharma Limited Announces Approval of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong

No longer forecast to breakeven

InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Orelabrutinib in Combination with Tafasitamab + Lenalidomide in China

InnoCare Pharma Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Mantle Cell Lymphoma in Singapore

Third quarter 2022 earnings released: CN¥0.28 loss per share (vs CN¥0.17 profit in 3Q 2021)

Less than half of directors are independent

InnoCare Pharma Limited to Report Nine Months, 2022 Results on Nov 11, 2022

InnoCare Announces First Adolescent Patient Dosed in Clinical Trial of pan-TRK Inhibitor ICP-723 in China

InnoCare Pharma Limited has completed a Follow-on Equity Offering in the amount of CNY 2.672498 billion.

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in China

InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China

InnoCare Pharma Limited Announces Priority Review of Orelabrutinib for the Treatment of R/R MZL by NMPA

InnoCare Pharma Limited Announces Priority Review of Orelabrutinib for the Treatment of R/R MZL by NMPA

No longer forecast to breakeven

InnoCare Pharma Announces the Acceptance of the Biologics License Application for Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong

InnoCare Pharma and Keymed Biosciences Jointly Announce Approval of Clinical Trial of CCR8 Monoclonal Antibody CM369

First half 2022 earnings released: CN¥0.31 loss per share (vs CN¥0.16 loss in 1H 2021)

InnoCare Pharma Limited Provides Earnings Guidance for the Nine Months Ended 30 September 2022

InnoCare Pharma Announces Acceptance of Supplemental New Drug Application for Orelabrutinib in Relapsed or Refractory Marginal Zone Lymphoma in China

Innocare Pharma Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

InnoCare Pharma Limited Announces First Subject Dosed in Clinical Trial of TYK2 JH2 Allosteric Inhibitor ICP-488 in China

Innocare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Boao Hope City’s Early Access Program

InnoCare Pharma Limited Announces Approval of Clinical Trial of Novel Targeted Protein Degrader Icp-490 in China

InnoCare Pharma Limited Announces First Patient Dosed in Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 in China

Innocare Announces Approval to Conduct A Phase II Clinical Trial of Tafasitamab in Combination with Lenalidomide in China

Forecast breakeven date pushed back to 2024

Less than half of directors are independent

InnoCare Presents Pre-Clinical Data of ICP-723 at AACR Annual Meeting 2022

Innocare Pharma Limited Announces Executive Changes

InnoCare Pharma Limited Announces Approval of Clinical Trial of TYK2 JH2 Allosteric Inhibitor ICP-488 in China

Insider recently bought HK$18m worth of stock

InnoCare Pharma Limited Announces Approval of Phase II Clinical Trial Using Orelabrutinib for the Treatment of NMOSD in China